Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: An open-label, randomised phase 3 trial

Robert J. Motzer, Camillo Porta, Nicholas J. Vogelzang, Cora N. Sternberg, Cezary Szczylik, Jakub Zolnierek, Christian Kollmannsberger, Sun Young Rha, Georg A. Bjarnason, Bohuslav Melichar, Ugo De Giorgi, Viktor Grünwald, Ian D. Davis, Jae Lyun Lee, Emilio Esteban, Gladys Urbanowitz, Can Cai, Matthew Squires, Mahtab Marker, Michael M. ShiBernard Escudier

Research output: Contribution to journalArticlepeer-review

200 Citations (Scopus)

Fingerprint Dive into the research topics of 'Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: An open-label, randomised phase 3 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences